Mirae Asset Sharekhan

#TopNews March 05, 2025 #Biocon: The company's subsidiary, Biocon Pharma has received final approvals for its two ANDAs - Lenalidomide capsules and Dasatinib tablets - from the US Food and Drug Administration (US FDA). Lenalidomide is used to treat multiple myeloma, mantle cell… https://t.co/XUjguL8B3r #TopNews #Biocon

Start your trading week with insightful Sharekhan's 3R research podcast. Today, we cover the following companies : 1. #UltraTechCementLtd 2. #BioconLtd 👉Watch now - https://youtu.be/BsBUvGOf8i4?si=NQyZqxh0yc_3v-IrDisclaimer - http://rb.gy/14y35#Sharekhan #Podcast #StockAnalysis #SharekhanPodcast #SharekhanKar #StockToBuyNow #StocksToBuy #UltraTechCementLtd #BioconLtd #Sharekhan #Podcast #StockAnalysis #SharekhanPodcast #SharekhanKar #StockToBuyNow #StocksToBuy

Start your #trading day with insightful #Sharekhan's 3R #research #podcast. Today, we cover the following companies: 1. Biocon Ltd 2. ICICI Lombard General Insurance Company Ltd Watch Now - https://youtu.be/g0Z6D7K6D0UDisclaimer - http://rb.gy/14y35 #stockupdate #bioconshareanalysis #icicilombard #StockAnalysis #SharekhanPodcast #trading #Sharekhan #research #podcast #stockupdate #bioconshareanalysis #icicilombard #StockAnalysis #SharekhanPodcast

#SharekhanResearch retains Buy rating on #Biocon(PT Rs 420); inks deal with Viatris’ to buy its biosimilar assets,… https://t.co/IRgfT0uLW8 #SharekhanResearch #Biocon

#SharekhanFNA #SharekhanResearch retains Buy rating on #Biocon(PT Rs 470) #Q3FY22 rev & PAT clock double digit gwth… https://t.co/YPiAq1MWaz #SharekhanFNA #SharekhanResearch #Biocon #Q3FY22

#SharekhanFNA #SharekhanResearch retains Buy rating on #Biocon(PT Rs 470) #Q2FY22 was healthy qtr; reducing impact… https://t.co/2GLe8j9M4p #SharekhanFNA #SharekhanResearch #Biocon #Q2FY22

#SharekhanFNA #SharekhanResearch retains Buy rating on #Biocon(PT Rs 470) #Q1FY22 was a weak qtr & results missed e… https://t.co/iEpiyfAKtx #SharekhanFNA #SharekhanResearch #Biocon #Q1FY22

#SharekhanResearch retains Buy rating on #Biocon (PT Rs 470) #Q4FY21 was a weak qtr; Biologics to be key growth dri… https://t.co/Nd8ghOCRGT #SharekhanResearch #Biocon #Q4FY21

#SharekhanFNA #SharekhanResearch retains Buy recommendation on #Biocon (PT Rs 520); Expected traction in existing b… https://t.co/FfRjqyX97f #SharekhanFNA #SharekhanResearch #Biocon